ArkBio is a global biotech company focused on developing innovative therapies for respiratory, infectious, and pediatric diseases. Founded in 2014, it has built core technology platforms and a differentiated R&D pipeline through in-house research and collaborations. Key assets include ziresovir, the first direct-acting RSV antiviral with positive pivotal phase III results globally, and AK0901, an FDA-approved pediatric ADHD therapy with ArkBio’s commercialization rights in Greater China.
ArkBio has established strategic partnerships with several multinational pharmaceutical companies and academic institutes, including Roche, Genentech, the Scripps Research Institute, the Institute of Microbiology, Chinese Academy of Sciences, domestic and international biotechnology companies, as well as venture investment institutions.
Company Details
- Employees
- 15
- Founded
- 2013
- Address
- Building 25, Lane 388, Shengrong Road, Shanghai,china
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.arkbiosciences.com
- Keywords
- Biotechnology, Pharmaceutical, RSV, IPF, ADHD, FLU, Pediatric.
- HQ
- Shanghai
Ark Biosciences Questions
Ark Biosciences's website is http://www.arkbiosciences.com
Ark Biosciences's LinkedIn profile is https://cn.linkedin.com/company/arkbiosciences
Ark Biosciences has
15 employees.
View email and phone details for 15
employees at Ark Biosciences.
Ark Biosciences's industry is
Biotechnology Research
Ark Biosciences's categories are Biotechnology Research
Ark Biosciences's founding year is 2013
